Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30 sept. 2021 19h06 HE
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2021...
Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA
27 sept. 2021 08h30 HE
|
Sarepta Therapeutics, Inc.
- Company Anticipates Part B of MOMENTUM to Serve as Pivotal Study for SRP-5051 and to Seek Accelerated Approval if Successful- Ambulatory and Non-Ambulatory Patients Between the Ages of 7 to 21...
Sarepta Therapeutics to Showcase Data from its Gene Therapy and RNA Platforms at World Muscle Society 2021 Virtual Congress
14 sept. 2021 08h30 HE
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the World Muscle Society...
Sarepta Therapeutics to Present at Upcoming Investor Conferences
07 sept. 2021 16h30 HE
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will...
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program
07 sept. 2021 08h30 HE
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced fifteen recipients of Route...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31 août 2021 17h57 HE
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on August 31, 2021...
Sarepta Therapeutics Announces Second Quarter 2021 Financial Results and Recent Corporate Developments
04 août 2021 16h05 HE
|
Sarepta Therapeutics, Inc.
Sarepta announces successful completion of end-of-phase-2 meeting for SRP-9001 micro-dystrophin with FDA’s Office of Tissues and Advanced Therapies (OTAT) and plans to initiate pivotal trial,...
Sarepta Therapeutics Executes Licensing Agreement for Gene Therapy Program from Nationwide Children’s Hospital to Treat Limb-Girdle Muscular Dystrophy Type 2A
04 août 2021 08h30 HE
|
Sarepta Therapeutics, Inc.
– Limb-girdle muscular dystrophy type 2A is the most common form of LGMD, accounting for a third of LGMD diagnoses – Sarepta’s unrivaled portfolio of investigational gene therapies for LGMD offers...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30 juil. 2021 17h42 HE
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., July 30, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 30, 2021 that...
Sarepta Therapeutics to Announce Second Quarter 2021 Financial Results and Recent Corporate Developments on August 4, 2021
28 juil. 2021 08h30 HE
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., July 28, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2021 financial...